Elixir Medical Completes Enrollment in Bioadaptor Randomized

Trial is evaluating DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance.

Related Keywords

Japan , Kanagawa , Fukushima , United States , New Zealand , Coll Cardiol , Shigeru Saito , Austrian Wiktor Stent Study Group , Catheterization Laboratory At Shonan Kamakuru , Elixir Medical , Dynamx Coronary Bioadaptor System , Dynamx Bioadaptor , Resolute Onyx , Catheterization Laboratory , Shonan Kamakuru General Hospital , Circ Cardiovasc , Year Follow Up , Randomized Controlled Trial , Paclitaxel Eluting Stents , Coronary Revascularization , Varying Outcomes With , Absorb Bioresorbable Vascular Scaffold During , Systematic Meta Analysis , Individual Patient Data Pooled , Wiktor Stent Study Group , European Paragon Stent , Cardiovascular Revascularization Medicine ,